Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | DDIT3 | P35638 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 7/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518396 | 0.81 | MMP13 (0.42) | HTR2AKCNH2HTR2CDDIT3MMP13 | |
| SCHEMBL5755791 | 0.80 | CA1 (0.55) | HTR2AKCNH2HTR2CMMP13MAPT | |
| SCHEMBL19454406 | 0.80 | DDB1 (0.54) | HTR2AKCNH2HTR2CMMP13DDB1 | |
| SCHEMBL20300384 | 0.80 | CA1 (0.53) | HTR2AKCNH2HTR2CDDIT3MMP13 | |
| SCHEMBL20323501 | 0.80 | HTR2A (0.47) | HTR2AKCNH2HTR2CDDIT3MMP13 | |
| SCHEMBL2536739 | 0.78 | HTR2A (0.46) | HTR2AKCNH2HTR2CNAMPT | |
| SCHEMBL31638145 | 0.77 | CA12 (0.58) | HTR2AKCNH2HTR2C | |
| SCHEMBL31638261 | 0.77 | CA2 (0.56) | HTR2AKCNH2HTR2CDDIT3NAMPT | |
| SCHEMBL31638199 | 0.76 | ALDH1A1 (0.48) | HTR2AKCNH2HTR2CDDIT3MMP13 | |
| SCHEMBL2894511 | 0.76 | CA2 (0.47) | HTR2AKCNH2HTR2CDDIT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044070-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD K.K. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7595316-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | HTR2A 70/4885KCNH2 1053/4885HTR2C 35/4885 |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | HRH3, HRH4, HRH2 | HTR2A 35/4885KCNH2 1611/4885HTR2C 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.